¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primary embryonic cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä, Ç÷±¸Çü¼º¼¼Æ÷À̽Ä
  • hairy cell
    Åиð¾ç¼¼Æ÷
  • hairy cell leukemia
    Åм¼Æ÷¹éÇ÷º´
  • hemolytic plaque-forming cell
    ¿ëÇ÷ÆÇÇü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ©Çü¼º¼¼Æ÷
  • hepatosplenic T-cell lymphoma
    °£ºñÀåT¼¼Æ÷¸²ÇÁÁ¾
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
  • heterotrophic cell
    Á¾¼Ó¿µ¾ç¼¼Æ÷
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
  • horizontal cell
    ¼öÆò¼¼Æ÷
  • horny cell
    °¢Áú¼¼Æ÷
  • human diploid cell vaccine
    »ç¶÷µÎ¹è¼ö¼¼Æ÷¹é½Å
  • human T-cell lymphoma/leukemic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁÁ¾/¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T-cell lymphotropic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁģȭ¹ÙÀÌ·¯½º
  • Hurthle cell adenoma
    ÈÖ¸£Æ²·¹¼¼Æ÷»ùÁ¾
  • hybrid cell
    ÀâÁ¾¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • leukemic cell
    ¹éÇ÷º´¼¼Æ÷
  • light cell
    ¹àÀº¼¼Æ÷
  • lipoid cell
    ÁöÁú¼¼Æ÷
  • luteal cell
    Ȳü¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
  • lymphokine-activated killer cell
    ¸²Æ÷Ä«ÀÎȰ¼º¼¼Æ÷µ¶¼º¼¼Æ÷
  • lymphopoietic cell
    ¸²ÇÁ±¸»ý¼º¼¼Æ÷
  • marrow cell
    °ñ¼ö¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mastoid air cell
    ²ÀÁö¹úÁý
  • matrix cell
    ±âÁú¼¼Æ÷, ÅйÙÅÁÁú¼¼Æ÷
  • memory cell
    ¸é¿ª±â¾ï¼¼Æ÷
  • Merkel cell-neurite complex
    Ã˰¢¼¼Æ÷½Å°æµ¹±âº¹ÇÕü
  • mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • Sezary cell
    ¼¼ÀÚ¸®¼¼Æ÷
  • T cell ; T lymphocyte ; thymus derived lymphocyte
    T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
  • T cell activating factor
    T¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • T cell cooperation
    T¼¼Æ÷Çùµ¿
  • T cell deficiency
    T¼¼Æ÷°áÇÌ
  • T cell factor (TCF)
    T¼¼Æ÷
  • T cell growth factor (TCGF, IL-2)
    T¼¼Æ÷ Áõ½ÄÀÎÀÚ
  • T cell hybridoma
    T¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • T cell immunity
    T¼¼Æ÷¸é¿ª
  • T cell leukemia
    T¼¼Æ÷(¹éÇ÷º´
  • T cell lymphoma
    T¼¼Æ÷¸²ÇÁÁ¾
  • T cell receptor
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü
  • T cell receptor gene
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü À¯ÀüÀÚ
  • T cell replacing factor
    T¼¼Æ÷ ´ëüÀÎÀÚ
  • T cell/lymphocyte
    T ¼¼Æ÷/¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • reticulofibrous membranous bone [primary membranous bone]
    ¼¼¸Á¼¶À¯¸·»À (ÀÏÂ÷¸·»À)
  • reticulofibrous membranous bone[primary membranous bone]
  • second primary molar
    Á¦ÀÌÀ¯±¸Ä¡(ð¯ì£êáÏ¿öÍ).
  • syphilis primaria =primary s. ³ª
    Á¦Àϱâ¸Åµ¶, Á¶±â¸Åµ¶.
  • tuberculosis,primary
    ÀÏÂ÷¼º, ¿ø¹ß¼º
  • tumor, occult primary
    Àẹ¿ø¹ßÁ¾¾ç
  • ventral primary ramus
    ¹èÂÊÀÏÂ÷°¡Áö, º¹ÃøÀÏÂ÷Áö(ÜÙö°ìéó­ò«).
  • wound healing,primary union
    ÀÏÂ÷À¯ÇÕ
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • acantholytic cell
    ±Ø¼¼Æ÷ÇØ¸®¼¼Æ÷
  • acanthome a cellules claires => clear cell acanthoma
  • accessory cell
    º¸Á¶¼¼Æ÷, ºÎ¼ö¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    ¼±Æ÷ ¼¼Æ÷(àÍøàá¬øà)
  • acinar cell
    ¼±¹æ¼¼Æ÷(¡­á¬øà)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
MCT manual cervical traction; mean cell thickness; mean cell threshold; mean circulation time; mean corp...
MCV mean cell volume; mean clinical value; mean corpuscular volume; median cell volume; motor conduction...
MRBC monkey red blood cell; mouse red blood cell
NRBC National Rare Blood Club; normal red blood cell; nucleated red blood cell
NSC neurosecretory cell; no significant change; nonservice connected; nonspecific suppressor cell; norma...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
PPA Primary Progressive Aphasia
PPP Primary Proliferative Polycythaemia
PPH Primary Pulmonary Hypertension
PRP Primary Raynaud's Phenomenon
PSC Primary Sclerosing Cholangitis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • killer T-cell
    ¼¼Æ÷ »óÇØ¼º T ¼¼Æ÷, ¼¼Æ÷»ì¼º T ¼¼Æ÷, »ìÇØ¼º T ¼¼Æ÷, ¼¼Æ÷»ìÇØ¼º T ¼¼Æ÷
  • labile cell
    ºÒ¾ÈÁ¤ ¼¼Æ÷
  • lacrimoethmoid cell
    ´©°ñ »ç ºÀ¿Í
  • lactotropic cell
    ÇÁ·Î¶ôƾ ºÐºñ ¼¼Æ÷
    µ¿ÀǾî=lactotro
  • lacunar cell
    ¼Ò¿Í ¼¼Æ÷
    Reed-Stemberg ¼¼Æ÷ÀÇ º¯ÇüÀ¸·Î¼­ ¶Ñ·ÇÇÑ ¼¼Æ÷¸· ¾È¿¡ Á¸ÀçÇϴ dzºÎÇÑ ¼¼Æ÷Áú¿¡ µÑ·¯½ÎÀÎ ´ÜÀÏ ÇÙÀ» °¡Áö°í ÀÖ´Ù.
  • lamina IV cell
    Á¦4Ãþ ¼¼Æ÷
    1. µÕ±Û°í »ï°¢Çü ȤÀº º° ¸ð¾çÀÇ ½Å°æ ¼¼Æ÷°¡ ³ôÀº ¹Ðµµ·Î ¹è¿­µÇ¾î ÀÖ´Ù. 2. °¡º­¿î Á¢ÃË °°Àº ³·Àº ¿ªÄ¡ÀÇ Àڱؿ¡ ¹ÝÀÀÇÑ´Ù.
  • laminar I cell
    Á¦ 1Ãþ ¼¼Æ÷
    1. ÀÛ°í Áß°£ Å©±âÀÇ ¼¼Æ÷¿Í ºÐ»êµÇ¾î ÀÖ´Â Å« ¹æÃßÇüÀÇ ¼¼Æ÷µé·Î ±¸¼ºµÈ´Ù. 2. Èİ¢ÀÇ º¼·ÏÇÑ Ç¥¸é¿¡ ÆòÇàÇÏ°Ô ¹è¿­µÇ¾î ÀÖ´Ù. 3. ¿£ÄÉÆÈ¸°, ½áºê½ºÅº½º P¸¦ ÇÔÀ¯Çϰí ÀÖ´Ù.
  • laminar II cell
    Á¦ 2Ãþ ¼¼Æ÷
  • laminar ¥± cell
    Á¦ 2Ãþ ¼¼Æ÷
    Á¦ 2ÃþÀÇ ¼¼Æ÷´Â 2Á¾·ù°¡ Àִµ¥ ÃþÀÇ ¹Ù±ù ÂÊ 1/4´Â ´õ¿í ÀÛÀº ¼¼Æ÷·Î ÅëÁõ°ú ¿­¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ°í, ¾È ÂÊ 3/4´Â Á» ´õ Å« ¼¼Æ÷·Î ¹«µ¶¼ºÀÇ ±â°è¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Ù.
  • Langerhans cell
    ¶û°Ô¸£Çѽº ¼¼Æ÷, Ç¥ÇÇ¼Ó Å« Æ÷½Ä¼¼Æ÷
    µ¿ÀǾî=intrae
  • large cell
    ´ë¼¼Æ÷
    ƯÁ¤ ÀÌÀ¯°¡ ÀÖ¾î
  • LE cell
    LE ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
    µÕ±Û°í, ±ÕÁú·Î º¸ÀÌ´Â ºÀÀÔü¸¦ ޽ÄÇÑ ¼º¼÷ È£Áß±¸¼º ´ÙÇÙ ¹éÇ÷±¸. ±× ºÀÀÔü ÀÚü´Â ´Ù¸¥ È£Áß±¸¿¡¼­ À¯·¡µÈ °ÍÀÌ´Ù. È«¹Ý¼º ·çǪ½º¿¡ ƯÀ¯ÇÑ °ÍÀÌÁö¸¸ °áÇÕ Á¶Á÷ÀÇ À¯»çÇÑ Áúȯ¿¡¼­µµ °üÂûµÈ´Ù.
  • lingual benign giant cell tumor
    ¾ç¼º °Å´ë ¼¼Æ÷ ¼³ Á¾¾ç
  • lupus erythematosus cell
    È«¹Ý¼º ·çǪ½º ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
  • M-cell
    M ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
carcinoma, acinar cell A malignant tumour arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (latin racemosus, full of clusters) refers, as does acinar (latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumour appears in all age groups and is most common in women.
(12 Dec 1998)
carcinoma, basal cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs.
(12 Dec 1998)
carcinoma, giant cell An epithelial neoplasm characterised by unusually large anaplastic cells. It is highly malignant with fulminant clinical course, bizarre histologic appearance and poor prognosis. It is most common in the lung and thyroid.
(12 Dec 1998)
carcinoma, islet cell A carcinoma of the islets of langerhans.
(12 Dec 1998)
carcinoma, large cell A tumour of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic.
(12 Dec 1998)
carcinoma, merkel cell A carcinoma arising from merkel cells located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of merkel cell carcinoma, occurring generally in elderly patients.
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
carcinoma, renal cell Carcinoma of the renal parenchyma usually occurring in middle age or later and composed of tubular cells in varying arrangements. It was first described in 1826. Possible causal factors are environmental, hormonal, cellular, and genetic. Smoking is a definite risk factor and obesity is associated with increased risk. Renal cell carcinoma accounts for approximately 3% of adult cancer; the male-female ratio is 2:1. It is more common among urban residents than rural.
(12 Dec 1998)
carcinoma, signet ring cell A highly malignant, mucus-secreting tumour in which the mucus-secreting cells are anaplastic and appear rounded, with the nucleus displaced to one side by a globule of mucus in the cytoplasm.
(12 Dec 1998)
carcinoma, small cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterised by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. There are admixtures of small cell lung carcinoma with other types of lung cancer. Small cell carcinomas are distinguished by their distinctive biological features, response to chemotherapy and radiotherapy, and by their nearly universal tendency to develop overt or subclinical metastases, which frequently eliminates surgery in most patients.
(12 Dec 1998)
carcinoma, squamous cell A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present.
(12 Dec 1998)
carcinoma, transitional cell A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence.
(12 Dec 1998)
cardiac cell Strictly speaking any cell of or derived form the cardium of the heart, but often used loosely of heart cells.
(18 Nov 1997)
packed cell volume <haematology> Measurement of the proportion of the blood occupied by the red blood cells. Normal values are 40-54% in males, 35-47% in females.
(13 Nov 1997)
packed red blood cell <haematology> Red blood cells collected from one individual that are packed into a small volume for transfusion into a patient.
(16 Dec 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á